ClinicalTrials.gg
Sign In
Status unknownNCT02980315Updated Dec 2, 2016

A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application

A Phase 1/2 interventional study of CAR-T cells in Nasopharyngeal Neoplasms, sponsored by The Second Hospital of Nanjing Medical University. Status unknown at 1 site in China. Per ClinicalTrials.gov, last updated 2016-12-02.

Sponsored by The Second Hospital of Nanjing Medical University · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2016), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety of the designed LMP1-CAR -T cells and determine whether the CAR-T cells are effective in the treatment of EBV associated malignant tumors.

Read the detailed description

Half of the patients will treat with LMP1-CAR-T cells,while the other half will receive a placebo.During the time of the treatment ,we will supervise the side effect of treated group.At last we compare the survival rate and health condition of the two groups.

02

Conditions studied

  • Nasopharyngeal Neoplasms

Keywords

  • nasopharyngeal carcinoma
  • EBV related cancers
03

In context

Nasopharyngeal Neoplasms

242 studies on the registry are indexed under Nasopharyngeal Neoplasms; 47 are open to participants now.

This study's planned enrollment of 20 is below the median of 59 across 199 interventional studies indexed under Nasopharyngeal Neoplasms.

Browse Nasopharyngeal Neoplasms studies →

Lead sponsor

The Second Hospital of Nanjing Medical University is the lead sponsor of 70 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of nasopharyngeal carcinoma

Exclusion criteria

Exclusion Criteria:

  • •pregnant woman

    • severe autoimmune diseases
    • serious infection
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    CAR-T cells

    the group treat with CAR-T cells

    Other: CAR-T cells

  • No intervention
    placebo

    the group treat with CAR-T cells

Interventions

  • OtherCAR-T cells

    the patients treat with CAR-T cells

    Also known as: adoptive immunotherapy

06

What researchers measure

Primary outcomes

  1. all cause mortality

    Time frame: one year

07

Study locations

1 of 1 sites recruiting
  • SecondNanjingMU
    Nanjing, Jiangsu 210000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2016, a primary completion of Dec 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2016
First posted
Dec 2, 2016
Start
Nov 2016
Primary completionEst.
Dec 2017
CompletionEst.
Dec 2017
Last update
Dec 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02980315
Lead sponsor
The Second Hospital of Nanjing Medical University
Responsible party
Sponsor
First posted
Dec 2, 2016
Start date
Nov 2016
Primary completion
Dec 2017 (estimated)
Completion
Dec 2017 (estimated)
Last update
Dec 2, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Nasopharyngeal Neoplasms →

Other studies from this sponsor

The Second Hospital of Nanjing Medical University

Start the discussion